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The lipid-sensor TREM2 aggravates 
disease in a model of LCMV-induced 
hepatitis
Lindsay Kosack1, Riem Gawish1,2,3, Alexander Lercher1, Bojan Vilagos1, Anastasiya Hladik1,2, 
Karin Lakovits1,2, Anannya Bhattacharya1,5, Christopher Schliehe1,6, Ildiko Mesteri4, Sylvia 
Knapp1,2 & Andreas Bergthaler1
Lipid metabolism is increasingly being appreciated to affect immunoregulation, inflammation and 
pathology. In this study we found that mice infected with lymphocytic choriomeningitis virus (LCMV) 
exhibit global perturbations of circulating serum lipids. Mice lacking the lipid-sensing surface receptor 
triggering receptor expressed on myeloid cells 2 (Trem2−/−) were protected from LCMV-induced 
hepatitis and showed improved virus control despite comparable virus-specific T cell responses. Non-
hematopoietic expression of TREM2 was found to be responsible for aggravated hepatitis, indicating 
a novel role for TREM2 in the non-myeloid compartment. These results suggest a link between 
virus-perturbed lipids and TREM2 that modulates liver pathogenesis upon viral infection. Targeted 
interventions of this immunoregulatory axis may ameliorate tissue pathology in hepatitis.
Immunoregulatory processes are crucial to maintain effective pathogen control while preventing excessive 
inflammation and immunopathology1–3. Next to epigenetic, transcriptional and post-transcriptional mecha-
nisms, the crosstalk between inflammatory and metabolic processes provides an additional layer of regulation4, 5. 
Lipids and their interactions with the immune system have received particular attention6–14 and have been 
implicated in inflammatory diseases such as metabolic disorders, atherosclerosis and rheumatoid arthritis15–17. 
A central hub of lipid metabolism is the liver, which also provides a niche for viruses like hepatitis B virus 
(HBV) and hepatitis C virus (HCV)18, 19. Interestingly, lipids play a key role at the different stages of the viral 
life cycle including cell entry, replication and budding20–22. In turn, viral infections may result in alterations 
in the extracellular composition of lipid species, which are thought to influence inflammatory processes and 
disease progression23–26. This is exemplified by HBV and HCV, which rely on host lipid metabolism to establish 
a successful infection and at the same time induce changes in serum lipids in patients22, 25, 27–31. The precise 
mechanisms of how the host reacts to such changes and its impact on tissue pathology still remain to be fully 
explored.
Several lipid-sensors such as the G-protein coupled receptors sphingosine-1-phosphate receptors 
(S1PR1-S1PR5) and prostaglandin receptors (e.g. EP2 and EP4) are already known to be involved in immunoreg-
ulation and antiviral immune responses10, 32, 33. Recently, the surface receptor triggering receptor expressed on 
myeloid cells 2 (TREM2), which previously was reported to bind anionic ligands and apolipoprotein E (ApoE)34–37, 
was shown to sense glycerophospholipids and sphingomyelins38, 39. TREM2 is a member of the immunoglob-
ulin (Ig) superfamily and is expressed on many cell populations including Kupffer cells, microglia, alveolar 
macrophages, bronchial epithelial cells and peritoneal macrophages40–44. It signals through the adaptor pro-
tein DNAX activation protein 12 (DAP12), which results in downstream signal transduction events including 
the phosphorylation of phospholipase (PL) Cγ and extracellular signal-related kinase (ERK) 1/2 as well as the 
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modulation of peroxisome proliferator-activated receptor-δ (PPAR-δ) activity43, 45, 46. In addition, DAP12 is asso-
ciated with numerous other cell surface receptors having either activating or inhibitory downstream effects on 
immunoregulation47, 48.
TREM2 deficiency in macrophages, dendritic cells and microglia leads to increased production of 
pro-inflammatory cytokines upon stimulation with toll-like receptor ligands49–52. Likewise, Trem2−/− bone 
marrow-derived macrophages and peritoneal macrophages produce increased levels of TNFα and IL-6 upon bac-
terial stimulation43, 53. Yet, there is evidence that TREM2 deficiencies can also attenuate inflammatory responses 
in macrophages and dendritic cells43, 54, 55 as well as in a brain injury model56, indicating that the function of 
TREM2 may vary in a context-dependent manner. Loss-of-function mutations in the human TREM2 gene have 
been linked to the fatal Nasu-Hakola disease, which is associated with bone fractures, progressive dementia and 
epileptic seizures57, 58. Recent genome-wide association studies identified the missense mutation R47H in TREM2 
to confer an increased risk for Alzheimer’s disease (AD)38, 59, 60. These insights instigated increased interest in the 
biology of TREM2 with a primary focus on the central nervous system and bone tissue.
In this study we employed the model of lymphocytic choriomeningitis virus (LCMV), which represents 
a benchmark model of acute and chronic viral infection and results in hepatitis as a consequence of immu-
nopathological mechanisms61–64. We found that infection with LCMV perturbs the composition of circulat-
ing lipid species in wild type (WT) mice, which prompted us to investigate the role of the recently described 
lipid-sensing receptor TREM2. By using Trem2−/− mice we could identify a novel disease-aggravating role of 
non-hematopoietically-expressed TREM2 in virus-induced liver pathology.
Results
Viral infection perturbs the serum composition of metabolites. To investigate the changes in serum 
metabolites after virus infection, we infected WT mice with LCMV strain WE61, 63. Infected mice exhibited ele-
vated serum concentrations of the clinical hallmark parameters of hepatitis, alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) (Fig. 1A) and elevated serum concentrations of cholesterol (Fig. 1B). 
Next, we wanted to assess systemic changes of serum metabolites upon viral infection by a targeted metabo-
lomics approach. We infected WT mice with LCMV and collected sera before and during the peak of hepati-
tis. Quantification of 188 metabolites was performed by mass-spectrometry unveiling an enrichment of altered 
glycerophospholipid and sphingolipid species in the serum of infected mice on day 8 post infection (Fig. 1C, 
Table S1). Other metabolites such as acylcarnitines, amino acids and biogenic amines showed less drastic changes 
(Fig. 1C, Table S1). Of the quantified 91 different glycerophospholipids and 15 sphingolipids, we observed a com-
plex pattern of up- and downregulated individual lipid species at both two and eight days post infection (Fig. 1D, 
Fig. S1A). These lipids are a class of metabolites with intricate regulatory mechanisms and multiple known roles 
including the involvement in hepatocellular death and liver diseases65–67. Together, this data shows that LCMV 
infection perturbs the global serum composition of lipids including the upregulation of numerous species of 
glycerophospholipids and sphingolipids.
Lack of TREM2 ameliorates liver damage upon viral infection. TREM2 was recently revealed to be a 
lipid-sensing receptor that binds glycerophospholipids and sphingomyelin38. Indeed, addition of lipids extracted 
from sera of infected mice tended to increase the activity of Ppar-δ in WT but not in Trem2−/− cells (Fig. S1B)43. 
Similarly, individual lipid species, which were significantly upregulated in the sera of mice infected eight days 
previously, led to increased reporter activation in a TREM2-dependent manner (Fig. S1C).
After observing differential regulation of systemic lipid species after LCMV infection and their effects on a 
TREM2-dependent reporter system, we hypothesized a potential role for TREM2 in LCMV hepatitis. We infected 
Trem2−/− and WT mice and observed that mice lacking TREM2 lost less body weight compared to infected WT 
mice (Fig. 2A). This was associated with reduced serum concentrations of ALT and AST in infected Trem2−/− 
compared to WT mice (Fig. 2B,C). Moreover, Trem2−/− mice exhibited lower serum concentrations of two 
alternative parameters for liver damage, alkaline phosphatase (AP) and bilirubin, compared to WT mice upon 
viral infection (Fig. 2D,E). In line with these findings, a histological assessment of liver damage revealed a lower 
pathological score (Fig. 2F) and fewer cleaved Caspase 3+ cells (Fig. 2G) in infected Trem2−/− mice compared to 
WT mice. Yet, serum concentrations of the kidney-related parameters blood urea nitrogen and creatinine were 
comparable between infected WT and Trem2−/− mice (Fig. S2A,B), suggesting that the differences in tissue dam-
age were not generalized to all organs. We also performed a metabolic profiling of Trem2−/− mice on day 8 post 
infection and found significant changes in the lipid profiles compared to WT mice, likely reflecting the extent of 
pathology (Table S1). In summary, the lack of TREM2 resulted in an unexpected amelioration of LCMV-induced 
liver damage.
Trem2−/− mice show improved virus clearance. To investigate viral propagation in WT and 
Trem2−/− mice, we determined the infectious viral loads by focus-forming assay (Fig. 3A–C). Both geno-
types had comparable viral loads in the serum until day six (Fig. 3A). At later time points, however, Trem2−/− 
mice exhibited reduced viral loads in serum (Fig. 3A), liver (Fig. 3B) and spleen (Fig. 3C) compared to WT 
mice. These findings were corroborated by immunohistochemical staining of liver sections, whereby reduced 
amounts of the viral nucleoprotein (NP) in Trem2−/− mice compared to WT mice were detected at 8 days post 
infection (Fig. 3D). Hepatocytes and Kupffer cells are the most abundant cell types in the liver and represent 
the primary target of LCMV in this organ61. We thus quantified the signal of viral NP in these cell populations 
and detected reduced numbers of NP+ hepatocytes and NP+ Kupffer cells in Trem2−/− liver sections compared 
to WT mice (Fig. 3E,F). The lack of the cellular receptor TREM2 per se may affect viral entry or replication. We 
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therefore infected primary bone marrow-derived macrophages (BMDMs) from both genotypes but found sim-
ilar viral growth curves in WT and Trem2−/− BMDMs (Fig. S3). In summary, Trem2−/− mice show improved 
viral clearance compared to WT mice.
WT and Trem2−/− mice mount comparable T cell responses. Virus control in the LCMV model is 
dependent on T cells and the damage observed in LCMV-induced hepatitis is largely attributed to CD8 T cells63. 
To assess T cell responses in our model, we infected WT and Trem2−/− mice with LCMV and enumerated CD8+ 
effector memory (EM) and CD4+ EM T cells as well as viral antigen-specific CD8 and CD4 T cell responses 
from spleen and liver tissue by intracellular cytokine staining using flow cytometry (Fig. 4, Fig. S4). Infected 
WT and Trem2−/− mice had comparable percentage of EM T cells (Fig. S4), and indistinguishable CD8 T cell 
numbers of IFNγ single producers and IFNγ TNFα double producers upon peptide stimulation for the viral 
epitopes GP33–41, NP396–404 and GP276–286 in both liver and spleen (Fig. 4A,B). This experiment indicated that WT 
and Trem2−/− mice mount similar CD8 T cell responses upon viral infection. Likewise, we assessed the cytokine 
Figure 1. LCMV infection induces global changes in the composition of serum metabolites. WT mice were 
infected with LCMV strain WE, and serum was collected at various time-points post infection (A–D). Serum 
kinetics of (A) alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and (B) cholesterol 
(n = 5 mice per group). (A,B) Statistical significance was calculated by One-way ANOVA with Bonferroni 
correction comparing the different time points to day 0. Symbols in (A,B) represent the mean ± SEM. For 
targeted metabolomics (C,D), serum from uninfected mice and mice that were infected with LCMV 8 days 
previously was used (n = 4 mice per group). (C) Fold enrichment of the metabolite classes (glycerophospolipids, 
sphingolipids, biogenic amines, amino acids, acylcarnitines) was calculated using the relative proportion 
(number of significant metabolites from a specific metabolite class divided by the number of all significant 
metabolites measured) normalized to the number of measured metabolites of a specific metabolite class 
divided by the number of all measured metabolites. Members of the acylcarnitine class did not pass the 
threshold of fold-change >1.5 and p-value < 0.05. (D) Bubble plot of individual glycerophospholipids (circle) 
and sphingolipids (triangle) depicting fold-change (x-axis), p-value (y-axis) and the absolute change (size of 
symbols). Statistical significance of changed individual metabolites in sera of infected vs. uninfected mice was 
calculated with unpaired t-test (C,D). Red symbols in (D) reflect metabolites with a fold-change >1.5 and a 
p-value < 0.05.
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producing-capacity of virus-specific CD4 T cells from liver and spleen. To that end, we stimulated cells with 
peptides for the CD4 T cell epitopes GP61–80 and NP309–328 and analyzed IFNγ single producers and IFNγ TNFα 
double producers (Fig. 4C,D). In analogy to the CD8 T cell results, this analysis revealed comparable CD4 T cell 
responses in infected WT and Trem2−/− mice. In addition, CD8+ T cells from both WT and Trem2−/− mice were 
equally able to lyse target cells loaded with the viral epitope peptide GP33–41 in vivo (Fig. 4E), indicating compa-
rable CD8 T cell-mediated cytotoxicity. In line with this, WT and Trem2−/− mice exhibited comparable elevation 
of serum transaminases upon injection of concanavalin A (Fig. S5), a model of acute hepatitis which depends on 
generalized antigen-independent activation and recruitment of T cells to the liver68.
Together, we found that LCMV-infected WT and Trem2−/− mice mount comparable virus-specific CD8 and 
CD4 T cell responses in spleen and liver, suggesting that the observed differences in liver pathology and virus 
clearance are unlikely to be driven by T cell proliferation, migration, cytokine production or cytotoxicity.
We also profiled γ/δ T cells, NK cells, NKT cells, neutrophils and macrophages in spleen and liver of WT and 
Trem2−/− mice upon infection by flow cytometry (Fig. S6). This analysis revealed largely comparable numbers of 
cell populations albeit we noticed an increase of NK and NKT cells in Trem2−/− mice compared to WT mice on 
day 4 post infection (Fig. S6B,C,G,H).
Comparable cytokine responses in WT and Trem2−/− mice upon LCMV infection. In order to 
investigate the induction of cytokines before the peak of LCMV-induced hepatitis, we quantified protein concen-
trations of chemokine (C-X-C motif) ligand 1 (CXCL1), interleukin 6 (IL-6) and interferon alpha (IFNα) in sera 
of WT and Trem2−/− mice by ELISA (Fig. S7). This revealed comparable levels of IL-6 and CXCL1 in WT and 
Trem2−/−. Yet, Trem2−/− mice exhibited reduced levels of IFNα compared to WT mice upon LCMV infection.
Non-hematopoietic TREM2 aggravates LCMV induced hepatitis. To determine the cellular com-
partment relevant for the observed TREM2 dependent liver pathology, we performed a reciprocal bone mar-
row transfer (Fig. 5). As a subset of Kupffer cells is radio-resistant69, we additionally treated the chimeric mice 
with liposomal clodronate to ablate remaining Kupffer cells in irradiated mice as demonstrated previously62, 69. 
Reconstitution of bone marrow was confirmed by flow cytometry (Fig. S8). Subsequently, the four groups of chi-
meric mice were infected with LCMV and serum concentrations of ALT, AST, AP and bilirubin were determined 
(Fig. 5A–D). These results revealed reduced liver damage in WT - > Trem2−/− and Trem2−/− - > Trem2−/− chi-
meric mice, consistent with a loss of TREM2 in radio-resistant cells. In line with these results, chimeric mice lack-
ing non-hematopoietically expressed TREM2 showed reduced viral loads in hepatocytes (Fig. 5E–G). TREM2 is 
Figure 2. Trem2−/− mice are protected against LCMV-induced hepatitis. WT and Trem2−/− mice were 
infected with LCMV strain WE. (A) Body weight was monitored after LCMV infection (n = 5 mice per 
group, representative of ≥ two independent experiments). (B,C) Serum kinetics of alanine aminotransferase 
(ALT) (B) and aspartate aminotransferase (AST) (C) were measured after LCMV infection (n = 5 mice per 
group, representative of ≥ two independent experiments). (D,E) Serum levels of alkaline phosphatase (AP) 
(D) and bilirubin (E) were measured eight and ten days post infection (n = 5 mice per group, representative 
of two independent experiments). (F) Liver sections of infected WT and Trem2−/− were histopathologically 
scored (see Methods; n = 5 mice per group). (G) Liver sections of infected WT and Trem2−/− were stained for 
cleaved Caspase 3 and the number of positive cells in 10 fields was quantified (n = 4 mice per group). Statistical 
significance was calculated by (A–E) Two-way ANOVA with Bonferroni correction or by (F,G) unpaired t-test. 
Symbols respectively bars represent the mean ± SEM.
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expressed in macrophages but not at detectable levels in hepatocytes (Fig. S9A,B), which may suggest the involve-
ment of another non-hematopoietic cell population. Collectively, these experiments show that loss of TREM2 in 
the non-hematopoietic compartment results in ameliorated viral hepatitis.
Discussion
In this study, we report a novel pathogenic role for TREM2 that results in aggravated viral hepatitis. Mice lacking 
the lipid-sensor TREM2 and WT mice were analyzed using the model of LCMV-induced hepatitis, which is 
largely T-cell dependent63. Interestingly, we found reduced liver pathology in Trem2−/− mice compared to WT 
mice despite comparable virus-specific T cell responses. This may be due to accelerated virus clearance in the 
Trem2−/− mice and reduced virus spread from Kupffer cells to hepatocytes between day 4 and 8 post infection61. 
Of note, we found increased levels of NK and NKT cells in Trem2−/− mice compared to WT mice preceding the 
onset of liver pathology. This could indicate an involvement of these cell populations, which have been implicated 
in the control of LCMV70, 71. We also detected reduced levels of serum IFNα in Trem2−/− mice upon infection. 
It is tempting to speculate that IFNα which is known to impact not only the antiviral cellular state but also the 
interactions between NK and T cells72, could provide additional cues for the underlying molecular mechanisms 
that govern the observed virus-induced TREM2-dependent phenotype.
TREM2 appears to exert highly specific effects in a cell-type specific and possibly pathogen-specific manner. 
The discovery that TREM2 is involved in Alzheimer’s disease led to a strong focus on its role in the central nerv-
ous system (CNS)59, 60. However, many other studies suggest that TREM2, in addition to its important role in 
the CNS, plays an immunomodulatory role during infection. For example, TREM2 has been shown to promote 
the clearance of Pseudomonas aeruginosa keratitis73 and injection of bone marrow cells over-expressing TREM2 
improved bacterial phagocytosis in a model of cecal ligation and puncture74. In contrast, lack of TREM2 did not 
impact the outcome of bacterial peritonitis with Escherichia coli53 and TREM2 was found to aggravate pneumo-
coccal pneumonia and respiratory infection with Sendai virus43, 75.
Until now, TREM2’s effects were mainly attributed to its expression in macrophages, monocytes and dendritic 
cells. Thus, it is interesting that our results indicate that TREM2 expression in non-hematopoietic cells is involved 
in the observed pathology. TREM2 was not detectable in primary hepatocytes and we, thus, hypothesize that a 
non-hematopoietic cell population other than hepatocytes is exerting the detrimental effects of TREM2 observed 
Figure 3. Trem2−/− mice show improved virus clearance compared to WT mice. WT and Trem2−/− mice were 
infected with LCMV strain WE. (A–C) Viral loads from serum (A), liver (B) and spleen (C) were quantified 
by immunological focus assay (n = 4–5 mice per group, representative of two independent experiments (B,C), 
data pooled from two independent experiments (A). (D,F) Liver sections from infected WT and Trem2−/− mice 
were stained for LCMV nucleoprotein (NP). Representative images of 3 to 4 mice per condition are shown in 
(D) and NP+ hepatocytes and NP+ Kupffer cells were quantified (E,F). Scale bar represents 100 μM. Statistical 
significance was calculated by (A,E,F) Two-way ANOVA with Bonferroni correction or by (B,C) unpaired 
t-test. Symbols respectively bars represent the mean ± SEM.
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in our model of viral hepatitis. Further studies will need to address the potential involvement of radio-resistant 
liver-resident cell populations such as hepatic stellate cells and liver sinusoidal endothelial cells. In addition, we 
cannot rule out neither systemic effects from other cell types outside the liver such as TREM2-expressing adipo-
cytes76, nor a role for the soluble form of TREM275.
The seminal study of Wang et al. showed that TREM2 binds to phosphatidylcholines and sphingomye-
lins, assigning a lipid-sensing role to this surface receptor38. Interestingly, these are the lipid species we found 
altered in mice upon infection with LCMV. TREM2 may also sense apoptotic cells through exposed phos-
phatidylserines38. Additional studies implicated ApoE, which plays an important role in lipoprotein metab-
olism and in immune-related processes and diseases77–79, as another ligand for TREM234, 35, 37. ApoE−/− mice 
infected with LCMV develop exacerbated liver damage80, which may suggest the involvement of ApoE in 
the TREM2-dependent liver pathology. More recently, Trem1−/− mice were reported to be protected from 
LCMV-induced hepatitis despite normal CD8 T cell responses81. TREM1, whose physiological ligands include 
peptidoglycan recognition protein 1 and likely others82, was found to be mostly expressed in neutrophils and 
suggested to modulate their inflammatory activity. Our bone marrow chimera experiments indicate that TREM2 
is unlikely to play a role in neutrophils, which is supported by the notion that TREM1 is typically expressed by 
activated neutrophils83, 84 while TREM2 is not. Thus, the fact that both Trem2−/− and Trem1−/− mice show a pro-
tective phenotype in viral hepatitis indicates distinct cell type-specific and non-redundant roles of these TREM 
family members in liver pathology.
The technological advancements in mass-spectrometry based lipidomics enable to map changes in the com-
position of circulating lipids during infection. Several studies have reported variations in serum levels of specific 
sphingolipids in chronic HBV and HCV patients and associated them with disease progression such as fibrosis 
and hepatic steatosis or antiviral treatment outcome25, 28–31. Systematic efforts will be needed to study the biology 
of individual lipid species in the context of liver pathology and other diseases. It will be crucial to investigate 
which species are released into the serum by active secretion and which may represent danger-associated molec-
ular patterns from cellular debris at a given time, through which receptors these lipids are sensed by cells and how 
signal transduction contributes to inflammation. In-depth knowledge about lipid metabolism, perturbations, 
Figure 4. WT and Trem2−/− mice show indistinguishable T cell responses. WT and Trem2−/− mice were 
infected with LCMV strain WE. (A,B) Single cell suspensions of liver and spleen were restimulated ex vivo with 
peptides GP33–41, NP396–404 and GP276–286. CD8+ T cells producing IFNγ and double-producing (DP) IFNγ and 
TNFα were quantified in the liver (A) and spleen (B) eight days post infection (n = 3 mice per group). (C,D) 
Single cell suspensions of liver and spleen were restimulated ex vivo with peptides GP64–80 and NP309–328. CD4+ 
T cells producing IFNγ and double-producing IFNγ and TNFα were quantified in the liver (C) and spleen (D) 
eight days post infection (n = 3 mice per group). Statistical significance was calculated by unpaired t-test. Bars 
represent the mean ± SEM. (E) Eight days post infection, virus-specific cytotoxic activity of CD8+ T cells from 
WT and Trem2−/− mice was measured using an in vivo cytotoxicity assay (n = 3–4 mice per group). Statistical 
significance was calculated by unpaired t-test. Bars represent the mean ± SEM.
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sensing and signaling in vivo will allow to identify disease-relevant dynamic patterns and assign prognostic value. 
It is understood that LCMV only shares certain features of immunobiology with HBV and HCV19, 85, 86, and lipid 
metabolism is known to differ considerably between mouse and man87, 88. Yet, this versatile experimental sys-
tem may provide valuable contributions to characterize infection-induced global changes in serum metabolites 
and dissect the affected downstream signaling cascades. Of note, Trem2−/− mice subjected to the concanavalin 
A-induced acute hepatitis model revealed elevated serum transaminases similar to WT mice, which may indicate 
that the TREM2-dependent pathology requires context-dependent parameters such as time kinetic, antigen spec-
ificity or distinct inflammatory milieus found in viral infections.
Our study revealed global changes in circulating lipids in the sera of LCMV-infected mice and identified a 
novel detrimental role for the non-hematopoietically expressed lipid-sensor TREM2 in a model of viral hepatitis. 
This may suggest novel ways to ameliorate virus-induced liver pathologies. Numerous additional functional links 
between infection-induced changes in serum metabolites and immunoregulation are expected to be uncovered4, 
which will allow novel insights into translational immmunometabolism of inflammatory and infectious diseases.
Methods
Mice. Trem2−/− mice52 (originally provided by Marco Colonna, Washington University, St. Louis) were back-
crossed onto a > 98% C57BL/6 background facilitated by genome-wide SSLP typing at 10 cM intervals (Speed 
Congenics Facility of the Rheumatic Diseases Core Center). Age matched 8–12 week old Trem2−/− mice and WT 
C57BL/6 controls were used for all experiments. CD45.1 mice89 (obtained from Jackson Laboratories, Bar Harbor, 
Stock No 002014) were used as controls for bone marrow chimera experiments. All experiments were conducted 
in individually ventilated cages under specific pathogen-free conditions at the Department for Biomedical 
Research of the Medical University of Vienna.
Figure 5. Non-hematopoietic TREM2 aggravates LCMV-induced hepatitis. (A–G) Chimeric mice were 
generated by reciprocal transfer of WT and Trem2−/− bone marrow and subsequently infected with LCMV 
strain WE. (A,B) Serum kinetics of alanine aminotransferase (ALT) (A) and aspartate aminotransferase (AST) 
(B) were measured after LCMV infection (n = 8–9 mice per group, data pooled from two similar experiments). 
(C,D) Serum levels of alkaline phosphatase (AP) (C) and bilirubin (D) were measured ten days post infection 
(n = 8–9 mice per group, data pooled from two similar experiments). (E–G) Liver sections from infected 
mice were stained for LCMV nucleoprotein. Representative images are shown in (E) and LCMV+ hepatocytes 
and Kupffer cells were quantified (F,G) (n = 8–9 mice per group, data pooled from two similar experiments 
harvested at 10 respectively 12 days post infection). Scale bar represents 50 μM. Statistical significance was 
calculated by (A–D) Two-way or by (F,G) One-way ANOVA with Bonferroni correction. Symbols respectively 
bars represent the mean ± SEM.
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For the generation of chimeric mice, bone marrow was harvested by flushing the femurs and tibias of donor 
mice as previously described90. Recipient mice (WT and Trem2−/−) were exposed to a single dose of γ-irradiation 
(9 Gy) and reconstitution of bone marrow cells was achieved by injecting 2 × 106 of the freshly isolated cells from 
WT or Trem2−/− donor mice. Four weeks later, chimeric mice were treated with 200 μg of anti-CD90 antibody 
intraperitoneally (i.p.), to deplete any remaining peripheral T cells from the recipient mouse. Another three weeks 
later, the mice received 100 μl of liposomal clodronate (ClodronateLiposomes.com) i.p., per 10 g of body weight to 
deplete any remaining macrophages from the recipient. > 4 weeks later mice were used for infection experiments.
Mouse infections. Mice were infected intravenously (i.v.) with 0.3–1 × 106 focus forming units of LCMV 
strain WE. LCMV WE was propagated on L929 cells (European Collection of Authenticated Cell Cultures 
(ECACC) Catalogue No.: 85011425). LCMV titers in serum and organs were determined by immunological 
focus forming assay as previously described62 albeit modified by using Vero cells (originally obtained from Daniel 
D. Pinschewer, University of Basel).
Targeted Metabolomics. Targeted metabolomics was performed using the AbsoluteIDQ p180 kit 
(Biocrates Life Sciences AG, Innsbruck, Austria). The kit allows the identification and quantitation of metabolites 
by LC- and flow injection analysis (FIA)-MRM. All serum samples were stored at −80 °C until being analyzed on 
an AB SCIEX QTrap 4000 mass spectrometer using an Agilent 1200 RR HPLC system, which were operated with 
Analyst 1.6.2 (AB SCIEX). The chromatographic column was obtained from Biocrates. The serum samples and 
additional blanks, calibration standards and quality controls were prepared according to the user manual. The 
experiments were validated with the supplied software (MetIDQ, Version 5-4-8-DB100-Boron-2607, Biocrates 
Life Sciences, Innsbruck, Austria). Quality controls were analyzed every 20th sample. Data was analyzed and 
visualized with R Studio. For metabolites that were below the limit of detection (LOD), the LOD was used for 
calculating fold changes and p-values.
Extraction of serum lipids and pure lipid species. Total lipids were extracted from sera from uninfected 
mice, and mice infected with LCMV WE eight days previously as follows; Briefly, 100 µl of serum was mixed with 
150 µl of 0.5 M KH2PO4, 750 µl of chloroform and 250 µl of methanol. The mixture was then vortexed for two 
minutes and then centrifuged for five minutes at 500× g at room temperature. The lower lipid phase was collected 
and stored at −80 °C, before being used to stimulate the cells 1:20.
The pure lipid species 1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine (16:1 (∆9-Cis) PC, Catalog No.: 
850358), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (16:0–18:2 PC, Catalog No.: 850458 P), 
N-stearoyl-D-erythro-sphingosylphosphorylcholine (18:0 SM (d18:1/18:0), Catalog No.: 860586) and 
N-palmitoyl-D-erythro-sphingosylphosphorylcholine (16:0 SM (d18:1/16:0), Catalog No.: 860584) were pur-
chased from Avanti Polar Lipids and solubilized as previously described8. Briefly, lyophilized lipids were reconsti-
tuted in ethanol:dodecane (98:2) and sonicated twice for five minutes at room temperature, vortexing in between. 
The lipids were then stored at −20 °C in glass vials with Teflon lids with an argon gas overlay, before being used to 
stimulate cells at a concentration of 15 µM.
Ppar-δ reporter assay. For a dual reporter assay (Promega E1960), MEFs were seeded at 2 × 105cells/ml, 
were transfected with PPRE luciferase promoter constructs (provided by Nikolina Papac, Medical University 
of Vienna) and a vector encoding PPAR-δ (provided by Ajay Chawla, University of California, San Francisco) 
using Lipofectamine LTX (Sigma Aldrich). On the next day, transfected cells were transferred to a 96-well plate 
at a density of 5 × 104/well and stimulated with either extracted lipids of uninfected or infected WT animals (see 
above) or pure lipid species (see above). Luciferase activity was measured after 48 h using the Dual-Luciferase 
Reporter Assay System according to the manufacturer’s instructions (Promega). pRenilla luciferase (Promega) 
activity was used to control the transfection efficiency. Background was measured in non transfected control cells 
and subtracted. All obtained luciferase values were normalized to renilla and plotted as fold change to untreated 
control cells.
Cell Culture. Primary hepatocyte isolation was conducted as previously described62. Bone marrow-derived 
macrophages (BMDMs) were generated as previously described43. Subsequently, cells were infected with LCMV 
at a MOI of 0.01 and harvested at the respective time points post infection for RNA isolation and real-time PCR 
analysis.
RNA isolation and real-time PCR. For measurement of gene expression by real-time PCR analysis, 
total RNA was isolated using QIAzol lysis reagent according to the manufacturer’s instructions (Qiagen). RNA 
was then reversed-transcribed into cDNA using the First Strand cDNA synthesis Kit (Fermentas). Subsequent 
gene expression was analyzed using TaqMan Fast Universal PCR Mastermix and TaqMan Gene Assays (Trem2: 
Mm04209424_g1 and Gapdh: 4352339E, Life Tech). Real-time PCR analysis was run on a StepOnePlus Real Time 
PCR system (Life Technologies). Gene expression was normalized to the housekeeping gene Eef1a162.
Blood chemistry. Mouse serum was pre-diluted 1:4 or 1:8 in PBS to determine levels of alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), bilirubin, blood urea nitrogen 
(BUN), cholesterol and creatinine using a Cobas C311 Analyzer (Roche).
Histology. Liver specimens were fixed for 24 hours at room temperature in 4% formaldehyde-PBS solution 
and paraffin embedded. After cutting, sections (3–4 μm) were deparaffinized using xylene and ethanol, stained 
with hematoxylin and eosin and a trained pathologist analyzed (blinded) liver pathology using a scoring system, 
considering lobular and portal inflammation as well as endothelitis and thrombus formation. Each parameter 
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was scored from 0 to 4 points, with 0 representing absent, 1 very mild, 2 mild, 3 moderate and 4 severe. For 
staining of cleaved caspase 3 and LCMV NP, antigen-retrieval was performed using citrate buffer pH6.0 (Vector 
laboratories) followed by blocking of endogenous peroxidase with 2% H2O2 and blocking steps using an avidin 
biotin blocking kit (Vector laboratories) and rabbit serum. Thereafter sections were incubated over night in either 
anti-cleaved caspase 3 antibody (Cell signaling) or anti-LCMV nucleoprotein rabbit serum. On the next day, 
the slides were washed with PBS and incubated with biotinylated swine anti-rabbit IgG (Dako) and developed 
using the Vectastain ABC kit (Vector laboratories) and DAB-HRP conjugate (Vector laboratories). After coun-
terstaining with hematoxylin and embedding, the sections were analyzed by light microscopy. From each mouse 
10 random pictures were taken with a 20-fold magnification and positive cells/field were counted by eye. For the 
LCMV positive cells, large polyglonal hepatocytes were distinguished from small spindle-shaped infected cells, 
which were considered as Kupffer cells61.
Flow cytometric analysis of immune cell populations. Single cells suspensions of liver and spleen tis-
sue were prepared by mechanical disruption using a 70 μm cell strainer. Absolute cell numbers were counted with 
a Neubauer Improved chamber Cells were stimulated with 10−6 μM of the respective peptides and subsequently 
stained with the antibodies CD8b.2 Pacific Blue (clone 54-5.8, Biolegend), B220 APC-eFluor 780 (clone RA3-6B2, 
eBioscience), IFNγ PE/Cy7 (clone XMG1.2, Biolegend), CD4 FITC (clone H129.19, Biolegend) and TNFα APC 
(clone MP6-XT22, Biolegend) as previously described62.
For testing the reconstitution of cells after bone marrow transplantation, we analyzed blood, liver and spleen 
of WT (CD45.2) mice that were reconstituted with bone marrow of CD45.1 congenic mice using the following 
antibodies: CD3 APC (clone 17A2, eBioscience), CD19 FITC (clone eBio1D3, BD), CD11b PerCP Cy5.5 (clone 
M1/70, eBioscience), CD45.1 Pacific blue (clone A20, Biolegend) and Ly5.2 PE (clone 104, Biolegend). Flow 
cytometric measurements were performed on a FACS LSR II Fortessa and on FACS Calibur (BD, San Diego, 
California, United States).
For flow cytometric analysis of different immune cell subsets, livers were cut into small pieces. After incu-
bation in 0.05% collagenase/dispase and 0.01% trypsin inhibitor at 37 °C, liver samples were pressed through a 
40 µm cell strainer, centrifuged at 800 g for 5–10 min at 4 °C and resuspended in RPMI 1640. The suspension was 
then overlayed onto a 33% (vol/vol) Percoll Solution (15 ml) and centrifuged for 30 min at room temperature 
with no brake. The supernatant was aspirated and red blood cell lysis was performed. After further washing and 
centrifugation steps, leukocytes were incubated with the following antibodies and analysed by flow cytometry: 
NK1.1 eF450 (PK136, eBioscience), CD3 V500 (17A2 BioLegend), Ly-6C BV605 (HK1.4, BioLegend), F4/80 APC 
(BM8, BioLegend), γδTCR PerCP Cy5.5 (GL3 BioLegend), CD19 PE (6D5, BioLegend), CD11b PE Cy7 (M1/70, 
BD Pharmingen), Ly-6G (1A8, BioLegend), CD11c AF700 (N418, eBioscience).
In vivo Cytotoxicity Assay. Cytotoxic activity of CD8+ T cells was measured as previously described91. 
Briefly, WT and Trem2−/− mice were infected with LCMV WE. Eight days post infection syngeneic splenocytes 
from uninfected C57BL/6 mice were pulsed with the LCMV immune-dominant epitope GP33-41 (KAVYNFATC) 
at a concentration of 10 µM in RPMI 10% FCS with 2-mercaptoethanol for 4 hours. GP33-41-pulsed and unpulsed 
cells were fluorescently labelled (Cell Proliferation Dye eFluor 450, eBioscience) at two different concentrations. 
After labelling, the two populations were mixed in equal ratios. Virus-infected or uninfected control mice were 
intravenously injected a total of 1.5 × 10^7 cells. Four hours later, the ratio of eFluorhi (GP33-41) and eFlourlow 
(unpulsed) cells was determined in the blood of recipient mice via flow cytometry. Specific killing was calculated 
as 100 – ([(% eFluorhi infected mouse/% eFluorlow infected mouse)/(% eFluorhi uninfected mouse/% eFluorlow 
uninfected mouse)] × 100).
Concanavalin A-induced acute hepatitis model. Mice were injected intraperitoneally (i.p.) with either 
concanavalin A (10 mg/kg, Sigma L7647) or PBS as control. Serum was collected at 24 hours post treatment.
Serum Cytokine Measurements. For quantification of systemic interferon alpha (IFNα), serum was 
pre-diluted 1:10 and detected by ELISA using rat anti-mIFNα capture antibody (PBL Assay Science 22100-1), 
rabbit anti-mIFNα detection antibody (PBL Assay Science 32100-1), peroxidase conjugated anti-rabbit secondary 
antibody (Jackson ImmunoResearch 711-036-152), TMB chromogen solution (Life Technologies 00-2023) and 
0.18 M H2SO4 stopping solution. Absorbance was read at 450 nm using a SpectraMax M5 (Molecular Devices) 
and used to calculate IFNα concentration as shown previously62. Systemic levels of interleukin-6 (eBioscience; 
88-7064-88) and CXCL1 (R&D Systems; DY453) were determined using commercial ELISA kits, following the 
manufacturer’s instructions.
Ethics Statement. All in vivo experiments were performed after approval by the Institutional Review Board 
of the Medical University of Vienna respectively the Veterinary University of Vienna and the Austrian Ministry 
of Sciences (permit numbers: BMWF-66.009/0318-II/3b/2012 and BMWFW-68.205/0032-WF/II/3b/2014) and 
in adherence to the Austrian law for animal experimentation.
Statistical analyses. Results are shown as line graph or bar graph with the mean + /− the standard error 
of the mean as indicated. Statistical differences between experimental groups were calculated by either unpaired 
t-test, One-way ANOVA or Two-way ANOVA with Bonferroni correction as indicated in the respective figure 
legends. Significant p-values were calculated as follows; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 or ****p ≤ 0.0001. 
Graphs and statistical tests were done with GraphPad Prism 6.
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